The company said May 5, 2025 annual meeting shareholders voted in person or by proxy, totaling 846,655,979 shares, representing approximately 89% of the 947,989,151 shares outstanding and entitled to vote as of February 26, 2025 record date.

1. 01

   The company said May 5, 2025 annual meeting shareholders voted in person or by proxy, totaling 846,655,979 shares, representing approximately 89% of the 947,989,151 shares outstanding and entitled to vote as of February 26, 2025 record date.

2. 02

   The company said the four director nominees, Ralph Alvarez, Mary Lynne Hedley, Kimberly Johnson and Juan Luciano, were elected to serve three-year terms ending at the 2028 annual meeting of shareholders. Alvarez received 724,174,318 votes for and 36,267,076 votes against.

3. 03

   The company said shareholders approved executive compensation on an advisory basis, with 731,376,577 votes for and 28,008,877 against. The appointment of Ernst & Young LLP as independent auditor for 2025 was approved with 805,143,438 votes for and 40,773,622 against.

4. 04

   Eli Lilly said the proposal to amend the articles to eliminate the classified board structure did not receive the required vote of 80% of outstanding shares, with 658,827,716 votes for. The proposal to eliminate supermajority voting provisions also did not meet the same requirement, with 655,797,749 votes for.

Analysis scope · Filing bodyWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.